Gilead Sciences, Inc.
News
Gilead Sciences goes ex-dividend tomorrow
SeekingAlpha.com: All News Gilead Sciences (GILD) announces $0.77/share quarterly dividend payable on Sept. 27 for shareholders of record on Sept. 13.\n more…
Gilead Unveils 'Remarkable Outcomes' From Late-Stage Lenacapavir Study Showing Promise In Preventing HIV Infections
Benzinga Gilead Sciences' Phase 3 trial results show twice-yearly HIV-1 capsid inhibitor lenacapavir reduced HIV infections by 96%, outperforming once-daily Truvada. Global regulatory filings are expected by the end of 2024, potentially supporting a 2025 launch.\n more…
Helping End HIV - Gilead Sciences
Accesswire NORTHAMPTON, MA / ACCESSWIRE / September 12, 2024 / Each scientific discovery gets us one step closer to our shared goal of ending the HIV epidemic. As a leader in HIV treatment and prevention, we'll...\n more…
Gileads Twice-Yearly Lenacapavir for HIV Prevention Reduced HIV Infections by 96% and Demonstrated Superiority to Daily Truvada in Second Pivotal Phase 3 Trial
Business Wire Gilead Sciences, Inc. (Nasdaq: GILD) today announced the results of an interim analysis from a second pivotal Phase 3 clinical trial investigating the use of the companys twice-yearly injectable...\n more…
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know
Zacks Investment Research Gilead Sciences (GILD) closed at $81.01 in the latest trading session, marking a -0.53% move from the prior day. This change lagged the S&P 500's 1.07% gain on the day. Meanwhile, the Dow experienced...\n more…
